IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens
Table 1
Baseline characteristics of patients in the present study.
All patients,
Patients with dual therapy,
Patients with triple therapy,
values (dual therapy versus triple therapy groups)
Gender, male/female
102/83
73/73
29/10
0.011
Age, years
56.2 ± 10.7
55.7 ± 11.2
58.2 ± 8.7
0.197
Previous treatment: naïve/relapse/null
119/45/21
102/26/18
17/19/3
0.0043 (naïve versus non-naïve)
AST, IU/L
57.1 ± 48.0
58.0 ± 48.7
53.9 ± 45.9
0.630
ALT, IU/L
70.4 ± 64.7
71.0 ± 64.9
68.1 ± 64.8
0.800
γ-GTP, IU/L
57.0 ± 66.7
56.4 ± 68.6
59.2 ± 59.8
0.816
Hemoglobin, g/dL
14.1 ± 1.3
14.0 ± 1.2
14.6 ± 1.3
0.0070
Platelets, ×104/mm3
16.6 ± 5.6
16.8 ± 5.8
16.0 ± 5.1
0.434
Treatment response
RVR,
42
15
27
<0.0001
EVR,
99
65
34
<0.0001
SVR/relapse/null
104/39/42
72/37/37
32/2/5
<0.0001
IFNL4, ss469415590, major/minor/ND
117/61/7
93/48/5
24/13/2
0.944
Peginterferon plus ribavirin with or without telaprevir therapy was defined as triple or dual therapy, respectively. Null: null response; AST: aspirate aminotransferase; ALT: alanine aminotransferase; γ-GTP: γ-glutamyltransferase; RVR: rapid virological response; EVR: early virological response; SVR: sustained virological response.
